立体定向消融放疗或手术治疗寡转移性激素敏感性前列腺癌:前瞻性临床试验的系统综述
该系统综述纳入4项前瞻性临床试验(n=169),评估立体定向消融放疗(SABR)或手术转移灶切除在寡转移性激素敏感性前列腺癌中的肿瘤学结局与安全性。早期无进展生存率为19%–60%,局部控制率达93%–100%,SABR的II级和III级毒性分别为8%和1%。结论认为转移导向治疗是有前景的实验性治疗策略,仍需随机对照研究明确其作用与最佳时机。
要点
- SABR或手术转移灶切除在寡转移性激素敏感性前列腺癌中局部控制率达93%–100%。
- 早期无进展生存率范围为19%–60%,SABR的III级毒性仅1%。
- 现有证据来自小样本前瞻性试验,需随机对照研究确认疗效与最佳时机。
核心结论
- 转移导向治疗是激素敏感性寡转移性前列腺癌有前景的实验性治疗策略。
- 需随机对照研究确认其在寡转移复发中的作用、最佳时机及对新发同步疾病的疗效。
研究设计与样本
- 系统检索Medline、Embase、Cochrane Review Database及临床试验数据库,纳入报告肿瘤学结局与安全性的临床试验。
- 从1025篇文章中纳入4项符合预设标准的临床试验,包括2项随机和2项非随机试验,共169例患者。
- 基线前列腺特异性抗原为2.0–17.0 ng/ml,年龄43–75岁,转移灶数目1–7个。
- 淋巴结转移占49.7%(84/169),骨转移占33.7%(57/169),淋巴结和骨转移占15.9%(27/169),内脏转移占0.5%(1/169)。
- 诊断影像采用传统影像者占43.7%(74/169),采用PET/CT者占56.2%(95/169);SABR占78.3%(94/120),手术转移灶切除联合SABR占21.6%(26/120)。
主要发现
- 早期无进展生存率范围为19%–60%。
- 局部控制率报告为93%–100%。
- SABR的II级和III级毒性分别报告为8%(8/100)和1%(1/100)。
- 手术并发症IIIa级和IIIb级分别报告为7.69%(2/26)和0%(0/26)。
临床怎么用
- 对于寡转移性激素敏感性前列腺癌患者,SABR或手术转移灶切除可作为实验性治疗选择,需在充分知情下个体化决策。
- 治疗决策时应评估转移灶数目、部位及影像学诊断方式,并关注SABR的II–III级毒性和手术并发症风险。
局限性
- 纳入研究仅4项、共169例患者,样本量小。
- 包含2项非随机试验,存在偏倚风险。
- 缺乏随机对照比较数据,无法确定转移导向治疗的最佳时机和确切疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Metastasis-directed therapy (MDT) in the form of stereotactic ablative radiation therapy (SABR), or in combination with surgical metastasectomy, may have a role in cancer control and disease progression. OBJECTIVE: To perform a systematic review of MDT (surgery or SABR) for oligometastatic (up to 10 metastases, recurrent or de novo) hormone-sensitive prostate cancer in addition to or following primary prostate gland treatment. EVIDENCE ACQUISITION: Medline, Embase, Cochrane Review Database, and clinical trial Databases were systematically searched for clinical trials reporting oncological outcomes and safety. The risk of bias was assessed with the Cochrane 2.0 or ROBINS-I tool. EVIDENCE SYNTHESIS: From 1025 articles identified, four clinical trials met the prespecified criteria. These included two randomised and two nonrandomised clinical trials (n=169). Baseline prostate-specific antigen level, age, and metastasis ranged from 2.0 to 17.0 ng/ml, 43 to 75 yr, and one to seven lesions, respectively. Nodal, bone, nodal and bone, and visceral metastases were present in 49.7% (84/169), 33.7% (57/169), 15.9% (27/169), and 0.5% (1/169) of patients, respectively. Diagnostic conventional imaging was used in 43.7% (74/169) and positron emission tomography/computerised tomography in 56.2% (95/169) of patients. SABR and surgical metastasectomy with SABR were used in 78.3% (94/120) and 21.6% (26/120) of patients, respectively. Early progression-free survival ranged from 19% to 60%. Local control was reported as 93-100%. Grade II and III SABR toxicities were reported in 8% (8/100) and 1% (1/100) of patients, respectively. Grade IIIa and IIIb surgical complications were reported in 7.69% (2/26) and 0% (0/26) of patients, respectively. CONCLUSIONS: MDT is a promising experimental therapeutic approach in men with hormone-sensitive oligometastatic prostate cancer. Randomised comparative studies are required to ascertain its role and optimal timing in oligometastatic recurrence and efficacy in de novo synchronous disease. PATIENT SUMMARY: We looked at the evidence regarding the use of surgery or radiotherapy at target areas of cancer spread in men with newly diagnosed or relapsed advanced (metastatic) prostate cancer. Evidence supports both treatment options as promising approaches, but further large trials are required.
引用
- Connor MJ, Smith A, Miah S, et al. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. Eur Urol Oncol. 2020. PMID: 32891600. doi:10.1016/j.euo.2020.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。